Tucotuzumab celmoleukin
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | EpCAM |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C7812H12124N2044O2408S60 |
| Molar mass | 175130.42 g·mol−1 |
| (verify) | |
Tucotuzumab celmoleukin is an anti-cancer drug. It is a fusion protein of a humanized monoclonal antibody (tucotuzumab) and an interleukin-2 (celmoleukin).[1][2][3]
This drug was developed by EMD Pharmaceuticals.
References
- ↑ Statement On A Nonproprietary Name Adopted By The Usan Council - Tucotuzumab Celmoleukin, American Medical Association.
- ↑ Clinical trial number NCT00016237 at ClinicalTrials.gov
- ↑ "Definition of tucotuzumab celmoleukin". National Cancer Institute.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.